The North Central Cancer Treatment Group (NCCTG) was founded in 1977 as an outreach effort of the Mayo Clinic Cancer Center to provide access to promising therapeutic interventions to patients residing in the sparsely populated upper Midwest region of the United States.

The North Central Cancer Treatment Group (NCCTG) is an international clinical research group sponsored by the National Cancer Institute. The NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical …

2008年10月1日 · The North Central Cancer Treatment Group (NCCTG) was founded in 1977 as a regional cooperative group to allow cancer patients in the upper Midwest of the United States to gain access to clinical trials in oncology by establishing a network of community oncology practices with one academic research base, the Mayo Clinic.

2015年6月20日 · NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Authors : Paul D. Brown , Anthony L. Asher , Karla V. Ballman , Elana Farace , Jane H Cerhan , S. Keith Anderson , Xiomara W. Carrero , …

Background: Two arms with FOLFIRI, with or without cetuximab, were initially included in the randomized phase III intergroup clinical trial NCCTG (North Central Cancer Treatment Group) N0147. When other contemporary trials demonstrated no benefit to using irinotecan as adjuvant therapy, the FOLFIRI-containing arms were discontinued.

2014年11月20日 · One of these reports, the joint analysis of North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in Treating Women With HER2-Overexpressing Breast Cancer) and the National Surgical Adjuvant Breast and Bowel Project NSABP B-31 (Doxorubicin and Cyclophosphamide Plus Paclitaxel With or …

This article details 30 years of achievements of the NCCTG, including important scientific contributions from disease-specific and treatment modality committees, the cancer control program, patient-reported outcomes and quality-of-life research, and biostatisticians that support the NCCTG's specific aims: to improve the duration and quality of ...

The North Central Cancer Treatment Group (NCCTG) study N0432 was a prospective, multicenter, single-stage phase II trial of first-line combination therapy with docetaxel, capecitabine, and bevacizumab in patients with MBC.

The N9741 trial led by the North Central Cancer Treatment Group (NCCTG) enrolled patients with metastatic colorectal cancer (MCRC) on combination chemotherapy regimens in the late 1990s through 2003.

2022年5月24日 · Gene expression analysis was performed in 1,268 samples from the North Central Cancer Treatment Group (NCCTG) N9831 and 244 samples from the NeoALTTO trial.